GT-1 has demonstrated excellent in vitro and in vivo activity against pathogens that have been identified by the World Health Organization as priority pathogens, including Acinetobacter spp. and P. aeruginosa, which can cause severe and often deadly infections, such as bloodstream infections and pneumonia.
Under the agreement between NIAID and Geom Therapeutics, the NIAID-supported Phase I clinical trial units for therapeutics plans to conduct a double-blind, placebo-controlled, dose-escalating study to assess the safety, tolerability and pharmacokinetics of single and multiple doses of GT-1 in healthy volunteers.
This trial will be conducted at Duke University.
GT-1 is a novel siderophore cephalosporin antibiotic and is being developed for the treatment of MDR Gram-negative bacterial infections that is actively transported into Gram-negative cells by exploiting iron uptake systems that use low molecular weight iron-binding molecules, known as siderophores, to transport iron into the cells.
This strategy facilitates the uptake of GT-1 into the bacterial periplasmic space in high concentrations where GT-1 binds to its penicillin-binding protein targets and disrupts cell wall synthesis, leading to cell death. The increased transportation into bacterial cells potentiates activity against Gram-negative bacteria, including activity against MDR Acinetobacter spp. and P. aeruginosa.
All IND-enabling studies have been completed for GT-1 and Geom Therapeutics plans to submit an IND to the FDA in 2H 2017.
Geom Therapeutics, a biotechnology company focused on the development of novel antibiotics for MDR Gram-negative infections, is a joint venture with LegoChem Biosciences, a publicly traded Korean biotechnology Company (KOSDAQ: 141080) and the inventor of GT-1.
NIAID conducts and supports research to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial